

Supporting Information

**Non-canonical Biosynthesis of the Brexane-Type
Bishomosesquiterpene Chlororaphen through Two Consecutive
Methylation Steps in *Pseudomonas chlororaphis* O6 and *Variovorax
boronicumulans* PHE5-4**

*N. Magnus**, *S. H. von Reuss**, *F. Braack*, *C. Zhang*, *K. Baer*, *A. Koch*, *P. L. Hampe*,
S. Sutour, *F. Chen*, *B. Piechulla*

Supporting Information

Table of Contents	Page
Supporting figures	
Figure S1: GC-EIMS chromatograms – controls for Figure 2	2
Figure S2: GC-EIMS chromatograms – VOCs from <i>Pc-ChloS</i>	3
Figure S3: GC-EIMS chromatograms – VOCs from <i>PchIO6_6044</i>	4
Figure S4: GC-EIMS chromatograms – VOCs from <i>V. boronicumulans</i> PHE5-4	5
Figure S5: Structure assignment of 4b , 5b and 6	6
Figure S6: Relative configuration of chlororaphen (6)	7 – 8
Figure S7: Relative configuration of γ -PSOH (4b)	9
Figure S8: Relative configuration of α -PCOH (5b)	10
Figure S9: (<i>E</i>)-configuration of γ -PSOH (4b) and α -PCOH (5b)	11 – 12
Figure S10: Amino acid alignment of <i>Pc</i> -FPP-MT and <i>Pc</i> - γ -PSPP-MT	13
Figure S11: Amino acid alignment of <i>Sp</i> -FPP-MT and <i>Pc</i> -FPP-MT	14
Figure S12: Amino acid alignment of <i>Sp</i> -SodS and <i>Pc</i> -ChloS	15
Figure S13: Amino acid alignment of <i>Sp</i> -SodS and <i>PchIO6_6044</i>	16
Figure S14: Amino acid alignment of <i>Pc</i> -FPP-MT and <i>Vb</i> -FPP-MT	17
Figure S15: Amino acid alignment of <i>Pc</i> - γ -PSPP-MT and <i>Vb</i> - γ -PSPP-MT	18
Figure S16: Amino acid alignment of <i>Pc</i> -ChloS and <i>Vb</i> -ChloS	19
Experimental procedures	
Heterologous gene expression in <i>E. coli</i> & Primers (Table S1)	20 – 21
<i>In vitro</i> enzyme assays	22
Pathway cloning in <i>E. coli</i>	22
Collection of volatiles	23
GC-EIMS analysis & Retention indices (Table S2)	23
NMR spectroscopy & NMR data (Table S3)	24 – 25
NMR spectra (Figures S17 – S42)	26 – 51
References	52

Supporting figures

Figure S1: GC-EIMS chromatograms of VOCs collected from *in vitro* assays with FPP (3a), SAM, and heterologously expressed enzymes showing negative controls for Figure 2 (IS1 = 5 ng/ μ L nonyl acetate as internal standard).




Figure S2: GC-EIMS chromatograms and mass spectra of VOCs collected from *in vitro* assays with FPP (**3a**), SAM, and heterologously expressed chlororaphen synthase (ChloS *PchlO6_6041* from *P. chlororaphis* O6 (IS1 = 5 ng/ μ L nonyl acetate as internal standard).




Figure S3: GC-EIMS chromatograms of VOCs collected from *in vitro* assays with heterologously expressed terpene synthase *PchlO6_6044* from *P. chlororaphis* O6 (IS1 = 5 ng/ μ L nonyl acetate as internal standard).




Figure S4: GC-EIMS chromatograms of VOCs collected from *in vitro* assays with heterologously expressed enzymes from *V. boronicumulans* PHE5-4 (IS1 = 5 ng/ μ L nonyl acetate as internal standard).




Figure S5: Structure assignment of γ -PSOH (**4b**), α -PCOH (**5b**) and chlororaphen (**6**) based on building blocks derived from H,H-correlations (*dqf*-COSY) and their linkages derived from relevant H,C-correlations (HMBC).




Figure S6a: relative configuration of chlororaphen (**6**, MM2 optimized model) derived from the NOESY spectrum (in C_6D_6).




Figure S6b: NOESY correlation of the vinyl protons of chlororaphen (**6**) (in C₆D₆).




Figure S7: relative configuration of γ -PSOH (**4b**, MM2 optimized model) derived from the NOESY spectrum (for *E*-configured allyl alcohol moiety see Figure S9).




Figure S8: relative configuration of α -PCOH (**5b**, MM2 optimized model) derived from the NOESY spectrum (for *E*-configured allyl alcohol moiety see Figure S9).




Figure S9a: (*E*)-configuration of allyl-alcohol moieties in γ -PSOH (**4b**) and α -PCOH (**5b**) as derived from their NOESY spectra.




Figure S9b: (*E*)-configuration of allyl-alcohol moieties in γ -PSOH (**4b**) and α -PCOH (**5b**) as derived from their NOESY spectra.




Figure S10: Amino acid alignment of farnesyl pyrophosphate methyltransferase *Pc*-FPP-MT (*PchlO6_6045*), which converts FPP (**3a**) into γ -PSPP (**4a**) and *Pc*- γ -PSPP-MT (*PchlO6_6042*) which converts γ -PSPP (**4a**) into α -PCPP (**5a**). Overall sequence identity was 41.25 % and sequence similarity was 57.59 %. Amino acid residues identified as part of the active site in *Sp*-FPP-MT from *S. plymuthica* 4Rx13 (which converts FPP (**3a**) into α -PSPP (**2a**))⁽¹⁾ are marked in grey when conserved and marked in yellow when different to *Sp*-FPP-MT. Alignment was performed using Clustal Omega with default settings.⁽²⁾

```

Pc-FPP-MT      MNQPTIDHNPLOPVTVRHGRALPYHVIRGAEVSGYEGKVVYTYQDDPEDWRKAIGDRLM 60
Pc- $\gamma$ -PSPP-MT -----MQVHKSALIEVIHSSTADHYQSKIESVYADPEEWRKVIQNEFW 43
                : : .**:: . *::: . * * **::**::**:::

Pc-FPP-MT      FQFGVYDDPRSRPPIISPDEGLRYFDRQMELAGYGRGDF--GPVKRILDVCGGWGFLKY 118
Pc- $\gamma$ -PSPP-MT YQYGVFDEKMDPSRLPLDASGRRHMEYQFELAEQAGADLSSQSIIRRAIDIGCGWGPVLSF 103
                :*:***: . : * ** *::: *:** . .*: :*: **::**:: *.:

Pc-FPP-MT      LADRFACPRLDGINISARQLEYCAKYHAEHRLSERINLYLCNAQVDLLPHADEPYDLV 178
Pc- $\gamma$ -PSPP-MT LAERYPHCERIDGVNVRPQLEYASQVISREGLAARVRLYLCNAKDIGALDPELPEYDLA 163
                **:*** * *:**:** * **::: . . * : * : **::**::* . ** . : **::

Pc-FPP-MT      TVRGVISHFPNDLYERSMAKLASRLRPGATVVISDNLNLPLEQYRSDTADDVDRACKH 238
Pc- $\gamma$ -PSPP-MT IFRGSLFHFTPQVLQETMQSLAQRMRPGGTVVISESLYKVDLATYQSFIPDKVDRASGH 223
                . ** : ** : : : * . ** . **::**::**::**::**::: * *:* * . ** * . *

Pc-FPP-MT      RKTFGYFRQVLEQCGLNVEDMRVLPENIDVARWFMDVKKNIETHFTPDTIPPPLEELRVM 298
Pc- $\gamma$ -PSPP-MT RKTFDLHKALEDNGFDVIDRRTIPSNEEVIRWYGLVKDNLDAHY-PDSRNPNFSELRDI 282
                **** . : : . ** : **::* * * : * . * : * ** : ** . **::**::* ** : * : ** :

Pc-FPP-MT      AVNVSVALIKDQFSTYSVIARHP 321
Pc- $\gamma$ -PSPP-MT AINSDALRKDKASSFSFIARRR 305
                * : . * ** * : * : **::**::

```


Figure S14: Amino acid alignment of cyclizing farnesyl pyrophosphate methyltransferases (FPP-MT) from *P. chlororaphis* O6 (*PchlO6_6045*) and *V. boronicumulans* PHE5-4 (*AO062_27010*), which convert FPP (**3a**) into γ -PSPP (**4a**). Overall sequence identity was 69.47 % and sequence similarity was 78.50 %. Amino acid residues identified as part of the active site in *Sp*-FPP-MT from *S. plymuthica* 4Rx13 (which converts FPP (**3a**) into α -PSPP (**2a**))⁽¹⁾ are marked in grey when conserved and marked in yellow when different. Alignment was performed using Clustal Omega with default settings.⁽²⁾

```

Pc-FPP-MT      MNQPTIDHNPVLPVTVRHGRALPYHVIRGAEVSGYEGKVVYTYQDDPEDWRKAI GDRIM      60
Vb-FPP-MT      MSTAT-----ARRIDAPAPPSLQVIRGAEANPYHAKVEYTYQDDPEDWRKAI GEDLM      52
                *  *                :                :*****. . * . ** *****: **

Pc-FPP-MT      FQFGVYDDPRS RPPISPDESGLRYFDQOMELAGYGRGDFGVPVKRIILDVCGGWGFLKYLE      120
Vb-FPP-MT      FQFGVYDDPRS VPPISLNESGLRYFDQOMEIAGLDQPPFPPIRRILDVCGGWGFLRYLA      112
                ***** * * * :*****:***:* . : * :*****:***

Pc-FPP-MT      DRFPACPRLDGINISARQLEYCAKYHAEHRLSERINLYLCNAQDVDLLPHADEPYDLVTV      180
Vb-FPP-MT      EHFQCRQLDGINISETQLAHCAR YHAQHLSDRVNLVLCDAQDVALLPNPDTTPYDLVTI      172
                ::* * :***** ** :*:***:~*:~*:~*:~*:~*:~*:~* * * * * * * * *

Pc-FPP-MT      RGVISHFPNDLYERSMAKLASRLRPGATVIIISDNLYNLPLEQYRSDTADDVDR LACKHRK      240
Vb-FPP-MT      RGVISHFPNDLYERSMKQVAARMRPGAKVVISDNLYNIPLDNYRSDIEDEVDR LACKHRK      232
                ***** :*:~*:~*:~*:~*:~*:~*:~* * :*****

Pc-FPP-MT      TPGYFRQVLEQCGLNVEDMRVLPENIDVARWFM DVKNIETHFTPD TIPPPEELRVM AV      300
Vb-FPP-MT      TPAYFRRVLEESGFVVEDMRVLPENIDVARWFT DVKENIEKNFTPD TIPPPEELRVM AV      292
                ** .***:***.~* : *****.***** ** :***.~*:~*:~*:~*:~*:~*

Pc-FPP-MT      NVSVALIKDQFSTYSVIARHP      321
Vb-FPP-MT      SLSVALIKNKFSTYSVIARRL      313
                .:*****:~*:~*:~*:~*:~*:~*

```

Figure S15: Amino acid alignment of γ -presodorifen pyrophosphate methyltransferases (γ -PSPP-MT) from *P. chlororaphis* O6 (*PchlO6_6042*) and *V. boronicumulans* PHE5-4 (*AO062_27015*), which convert γ -PSPP (**4a**) into α -PCPP (**5a**). Overall sequence identity was 73.29 % and sequence similarity was 82.74 %. Alignment was performed using Clustal Omega with default settings.⁽²⁾

```

Pc- $\gamma$ -PSPP-MT  --MQVHKSAIEVIHSSTADHYQSKIESVYADPPEEWRKVIGNEFWYQYGVFDEKMDPSRL  58
Vb- $\gamma$ -PSPP-MT  MQASAQAVGIDVIHSRLDHYQDKIEQVYADTPDQWRKAIGNELWYQYGVFDEKMDPHDL  60
                ..: .*:***** : *****.***.**** *::*****.*****:*****
                *

Pc- $\gamma$ -PSPP-MT  PLDASGRRHMEYQFELAEQAGADLSSQSIRRAIDIGCGWGPVLSFLAERYPHCERIDGVN  118
Vb- $\gamma$ -PSPP-MT  PLDASGRRHMEHQFELAEQAGADLSPATVRRRAIDIGCGWGPVLKFLAQRYPQCARIDGVN  120
                *****:***** :*****.*****.*:*****:*****
                *

Pc- $\gamma$ -PSPP-MT  VSRPQLEYASQVISREGLAARVRLYLCAKNDIGALPDPELPHYDLAIFRGSLSHFHTPQVLQ  178
Vb- $\gamma$ -PSPP-MT  VSRPQLECARELIAHEGLADRVRVLYQCNKDIGELPDAQVPYDLAILRGSLSHFHTPEVLE  180
                ***** * :*:***** ***** ***** * * :*****:*****:*****:***:
                *

Pc- $\gamma$ -PSPP-MT  ETMQSLAQMRPGGTVVISESLYKVDLATYQSFIPDKVDRAASGHRKTPDSLHKALEDNG  238
Vb- $\gamma$ -PSPP-MT  QAMASLSARMRTGGTVIISESLYKVDLATYKSHIPDKVDRAASGYRKTDPGVKQVLEPHG  240
                ::* **: *** *****:*****:*****.*.*****:*****:*****.:*:* :*
                *

Pc- $\gamma$ -PSPP-MT  FDVIDRRITPSNEEVIRWYGLVKNLDAHYPDSRNPNFSELRDIAINFSDALRKDKASSF  298
Vb- $\gamma$ -PSPP-MT  FAVLDQRVLPNSAEVIRWYGLVKNLDAHHPTSKTATFTELRLIAVVSFDALLKDKASSF  300
                * *:***: * * *****:*****:* *..*:*****:***** *****
                *

Pc- $\gamma$ -PSPP-MT  SFIARRR  305
Vb- $\gamma$ -PSPP-MT  SFIARRT  307
                *****
    
```

Figure S16: Amino acid alignment of the chlororaphen synthases (ChloS) from *P. chlororaphis* O6 (*PchlO6_6041*) and *V. boronicumulans* PHE5-4 (*AO062_27040*), which convert α -PCPP (**5a**) into chlororaphen (**6**). Overall sequence identity was 73.16 % and sequence similarity was 80.83 %. Alignment was performed using Clustal Omega with default settings.⁽²⁾

```

Pc-ChloS      MNHSAQALAPEVSFYIPEMYCSVLPRIHPDYPIIDERNASWVREFLPFTDEAAQLRFLRL 60
Vb-ChloS      MNYPDRIVFPEVSFHIPMFCSVPPKIHTDYPVIDERNAAWGREFLPFSDEATRLKFLRL 60
              **:  :  : *****:*****:*** *:** ***:*****:* *****:***:;*:****

Pc-ChloS      HTPMWDSMIFPIGSADRLVHTSCVTSLITAIDDMPLGRHAMFHDGEVALLEGHPFARAAQ 120
Vb-ChloS      HLPMWDCLLFPIGSADRIFLTSCVTGLILAIDDMPLGRHAVCGDGDVALLEGHPLARAAA 120
              * ****. : :*****: . ***** ** *****: ** :*****:****

Pc-ChloS      DIFGKLRQHMPAPVYRRYCQELQAWFESVEEARLVAAGKVLPLDEFLELRHPNTGLLPS 180
Vb-ChloS      DIFGRLRQSMSPQVYRRYCLEWKAWFDSVEVEAGLVAEGKVLPHYDEFALALRHPNTGLLPY 180
              ***:*** * ***** * :***:*** ** ** ***** **** *****

Pc-ChloS      FPVAEFLYDLDLTELLAQDRELQLAIRVTNEHVGLVNDILSHRKEHAIGVTLNAMESLRI 240
Vb-ChloS      FPVSEFIYDLDLTELLAQDADLQRAILATNEHVALVNDLLSHHKEHAVGVTLNAMESLRM 240
              ***:**:*****:*** ** * .***** .****:***:*****:*****:

Pc-ChloS      VHGSAQEAADILCQRIREADRARVELCEVLRHRYANRPDADRIGMYLDGLGRICAGNLR 300
Vb-ChloS      AHGRSPQEAADILCQRIREADRTRVDACELLRRRYAHRPDADRFGLYLDSFGLMCAGNLR 300
              .**:* *****:***: **:**:***:*****:***:***. :* :*****

Pc-ChloS      WLESDRYVDSRNGWDWTRSRLIVLDPEPAPALAQ 339
Vb-ChloS      WILENDRYVDSRNGWDWTRSRLVLDPEPAPALAQ 329
              *:* .*****:***

```

Experimental Procedures

Heterologous gene expression in *E. coli*

The *Pseudomonas chlororaphis* O6 methyltransferase (*Pc*- γ -PSPP-MT, *PchlO6_6042*; *Pc*-FPP-MT, *PchlO6_6045*) and terpene synthase genes (*Pc*-TPS1 (*Pc*-ChloS), *PchlO6_6041*; *Pc*-TPS2, *PchlO6_6044*) were obtained from genomic DNA. The *Variovorax boronicumulans* PHE5-4 methyltransferase (*Vb*-FPP-MT, *AO062_27010*; *Vb*- γ -PSPP-MT, *AO062_27015*) and terpene synthase gene (*Vb*-TPS (*Vb*-ChloS), *AO062_27040*) were codon-optimized for *E. coli* and synthesized by GENEWIZ Germany GmbH (Leipzig, Germany). Amplification of all genes and linearization of the expression vector was carried out with the Q5® High-Fidelity DNA Polymerase (New England Biolabs GmbH, Frankfurt am Main, Germany) according to the manufacturer's instructions using specific primers (Table S1). All genes were directionally cloned into the pE-SUMOstar Kan vector (LifeSensors, Malvern, PA, USA) by Gibson assembly (NEBuilder® HiFi DNA Assembly, New England Biolabs, Frankfurt am Main, Germany). Recombinant vectors were transformed into *E. coli* XL1-blue. Plasmids were checked for correct insertion by colony PCR using T7 primers, reisolated, sequenced, and finally transformed into *E. coli* BL21(DE3). For heterologous expression, positive transformants of *E. coli* BL21(DE3) were grown overnight at 37 °C in 10 mL LB liquid medium (8.0 g/L tryptone, 4.0 g/L yeast extract, 5.0 g/L NaCl) supplemented with 50 μ g/mL kanamycin. Main cultures were prepared in 200 mL LB liquid medium supplemented with kanamycin (50 μ g/mL) and 3 mM glucose and inoculated with 2 mL from the overnight cultures. Cultures were incubated at 37 °C and 170 rpm until an OD₆₀₀ of 0.8-1.0 was reached followed by induction of gene expression by addition of 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG). Finally, cultures were incubated for 20 h at 20 °C and 170 rpm before cells were harvested by centrifugation (10.000 xg, 15 min, 4 °C). Cell lysis and purification of the respective proteins was performed as previously described.^(3,4) Protein purity was confirmed by SDS-PAGE and the isolated proteins were stored at -70 °C.

Table S1: Sequences of primers used in this study. Small letters indicate overhangs complementary to the cloning site of the vector pE-SUMOstar Kan. Capital letters represent parts of the primers binding to the target gene.

name	sequence (5' → 3')	function
T7_fwd	TAATACGACTCACTATAGGG	verification of correct insertion
T7_rev	CCGCTGAGCAATAACTAGC	
SUMO_fwd	GATCCGGCTGCTAACAAAG	amplification of pE-SUMOstar Kan
SUMO_rev	ACCTCCAATCTGTTTCGCG	
6045_fwd	accggaacagattggaggtAACCAGCCCACCATCGATC	amplification of <i>Pc</i> -FPP-MT
6045_rev	gctttgtagcagccggatcTCAGGGGTGTCGCGCAAT	
6042_fwd	accggaacagattggaggtCAGGTACACAAGAGTGCGATTGAGGTC	amplification of <i>Pc</i> - γ PSPP-MT
6042_rev	gctttgtagcagccggatcCTAGCGCCTGCGCGCGAT	
6041_fwd	accggaacagattggaggtAACCATTCTGCACAGGCCCTC	amplification of <i>Pc</i> -TPS1 (<i>Pc</i> -ChloS)
6041_rev	gctttgtagcagccggatcTCAGCTCTGCGCGAGGGC	
6044_fwd	accggaacagattggaggtGAAACGCCTTCAGTCATTC	amplification of <i>Pc</i> -TPS2
6044_rev	gctttgtagcagccggatcTCATGACAATCGGGAAGG	
Vb_27010_fwd	accggaacagattggaggtAGTACCGCGACCGCGCGC	amplification of <i>Vb</i> -FPP-MT
Vb_27010_rev	gctttgtagcagccggatcTTACAGGCGGCGCGCAATCAC	
Vb_27015_fwd	accggaacagattggaggtCAAGCGAGCGCGCAAGCG	amplification of <i>Vb</i> - γ -PSPP-MT
Vb_27015_rev	gctttgtagcagccggatcTTAGGTGCGGCGCGCAATAAAG	
Vb_27040_fwd	accggaacagattggaggtAACTATCCGGATCGCATTGTG	amplification of <i>Vb</i> -ChloS
Vb_27040_rev	gctttgtagcagccggatcTTACGGGCGATCCAGCAC	
6041-6045_fwd	accggaacagattggaggtATGAACCAGCCCACCATCGATC	amplification of <i>PchlO6_6041-6045</i>
6041-6045_rev	gctttgtagcagccggatcTCAGCTCTGCGCGAGGGC	
6042-6045_fwd	accggaacagattggaggtATGAACCAGCCCACCATCGATCATAAC	amplification of <i>PchlO6_6042-6045</i>
6042-6045_rev	gctttgtagcagccggatcCTAGCGCCTGCGCGCGAT	

***In vitro* enzyme assays**

To functionally characterize the enzymatic activities of the purified proteins, different enzyme assays were performed *in vitro*. Investigation of methyltransferase activities was performed in coupled enzyme assays containing 20 µg of purified methyltransferase enzyme, 20 µL TRIS buffer (50 mM potassium acetate, 20 mM tris-acetate, 10 mM magnesium acetate, 100 µg/mL BSA, pH 7.9), 30 mM dithiothreitol, 2.3 mM of *S*-adenosyl methionine (Merck Sigma-Aldrich, Darmstadt, Germany), 0.06 mM of farnesyl pyrophosphate (FPP, **3a**, Echelon Biosciences, Salt Lake City, USA), and double distilled water (ad 190 µL). All constituents were mixed and incubated at 37 °C for 3 h 30 min. Afterwards, 10 U of shrimp alkaline phosphatase (New England Biolabs, Frankfurt am Main, Germany) was added and incubation continued for 1 h at 37 °C. Extraction of reaction products was conducted by addition of 200 µL hexane (containing 5 ng/µL nonyl acetate as internal standard) followed by 30 s vigorous shaking and centrifugation (2 min, 4000 g). Finally, the hexane phase was collected, and reaction products analyzed by GC-EIMS.

Combined methyltransferase (MT) and terpene synthase (TPS) activities were investigated in double (MT + TPS) and triple enzyme assays (FPP-MT + γ -PSPP-MT + TPS), respectively. 20 µg of each investigated enzyme were added to 50 µL HEPES buffer (250 mM HEPES–KOH, 100 mM MgCl₂, 2.5 mM MnCl₂, 50% (v/v) glycerol, pH 8), 30 mM dithiothreitol, 2.3 mM of *S*-adenosyl methionine (Merck Sigma-Aldrich, Darmstadt, Germany), 0.06 mM of farnesyl pyrophosphate (FPP, **3a**, Echelon Biosciences, Salt Lake City, USA), and double distilled water (ad 200 µL). After incubation for 3 h 30 min at 37 °C, reaction products were extracted with hexane as described above. To evaluate terpene synthase activity alone, single enzyme assays were prepared according to the double and triple enzyme assays without addition of purified methyltransferases.

Pathway cloning in *E. coli*

Different parts of the chlororaphen biosynthetic operon were cloned into pE-SUMOstar Kan and subsequently expressed in *E. coli* followed by collection of the produced volatile compounds. For γ -PSOH (**4b**) accumulation pE-SUMOstar Kan + *PchlO6_6045* was used. α -PCOH (**5b**) synthesis was achieved by simultaneous cloning of the genes *PchlO6_6042-PchlO6_6045* into pE-SUMOstar Kan. Finally, chlororaphen (**6**) synthesis was achieved by direct cloning of the genes *PchlO6_6041-PchlO6_6045* in pE-SUMOstar Kan. Cloning was performed via Gibson Assembly as described above and generated plasmids were checked for correct insertion via colony PCR and sequencing.

Collection of volatiles

Heterologous production of γ -presodorifenol (γ -PSOH, **4b**), α -prechlororaphenol (α -PCOH, **5b**), and chlororaphen (**6**) was performed in *E. coli* BL21(DE3) as a production host. For this purpose, overnight and main cultures were performed as described above. Following induction with 1 mM IPTG cultures were split and 100 mL each were transferred into a VOC collection system as previously described⁽⁵⁾ and incubated at 30 °C and 250 rpm. Volatiles collected on Porapak Q (80-100 mesh, Sigma-Aldrich, St. Louis, Missouri, USA) were eluted with C₆D₆ (99.96 % D, Deutero GmbH, Kastellaun, Germany), after 24 h (for chlororaphen (**6**) sampling) and 48 h (for sampling of **4b** and **5b**), respectively. Eluted samples were pooled for NMR analysis, and an aliquot was treated with *cis*-nerolidol as internal standard (final concentration 5 ng/ μ L) and analyzed by GC-EIMS.

GC-EIMS analysis

Hexane extracts of the enzyme assays and volatile compound eluates were analyzed by GC-EIMS using a GCMS-QP2010 Se system with a AOC-5000 PAL autosampler (Shimadzu Deutschland GmbH, Duisburg, Germany) equipped with a DB5-MS column (60 m x 0.25 mm x 0.25 μ m; J&W Scientific, Folsom, California, USA). Samples of 1 μ L were injected at 250 °C using either splitless mode for enzyme assays or 1:10 split ratio for volatile eluates. Helium was used as carrier gas at a flow rate of 1.1 mL/min. A temperature gradient was applied by starting from 35 °C for 2 min followed by an increase of 10 °C/min to 280 °C within 24.5 min, followed by 15 min at 280 °C. Electron ionization at 70 eV was used. Mass spectra were obtained using the scan mode (with m/z 40–280). Data analysis was performed with the Lab Solutions software (Shimadzu Deutschland GmbH, Duisburg, Germany). Kovats retention indices for the new compounds are shown in table S2.

Table S2: Kovats retention indices for γ -presodorifenol (γ -PSOH, **4b**), α -prechlororaphenol (α -PCOH, **5b**), and chlororaphen (**6**).


#	name	KI
4b	γ -PSOH	1773
5b	α -PCOH	1791
6	chlororaphen	1506

NMR spectroscopy


VOCs collected on Porapak Q were eluted with C₆D₆ (99.96% D) and the resulting solutions were concentrated to a total volume of 0.5 mL using a stream of nitrogen. NMR spectra of crude VOC mixtures were recorded using a 600 MHz Bruker Avance Neo Ascend instrument equipped with a 5 mm broad band inverse (BBI) probe. ¹H NMR, ¹³C NMR, *dqf*-COSY, HSQC, HMBC, NOESY. High resolution *dqf*-COSY spectra were recorded using phase cycling for coherence selection with a time domain of 8192 data points in F2 and 512 increments in F1. Heteronuclear HSQC and HMBC spectra were recorded using non-uniform sampling with a sampling rate of 50% by acquiring 512 scans. NOESY spectra (SW 6 ppm, 2048 in F2, 512 in F1, NS 32) were recorded using a mixing time of 0.7 s. NMR data of **4b**, **5b**, and **6** were recorded in C₆D₆ in the presence of approximately 100 equivalents of 1*H*-indole. 2D spectra were manually phased, zero-filled, using the MestreNova 14.2 software.

Table S3: NMR data of chlororaphen (**6**) and the hydrolysis products of its monocyclic biosynthetic intermediates γ -presodorifenol (**4b**) and α -prechlororaphenol (**5b**) from *P. chlororaphis* O6, along with α -presodorifenol (**2b**) from *S. plymuthica* 4Rx13 for comparison.⁽³⁾ (chemical shift (δ) in [ppm], multiplicity, coupling constant (J) in [Hz], in C_6D_6 with 99.96% D, **4b**, **5b**, **6** recorded in the presence of approximately 100 equivalents of 1*H*-indole).


	α -Presodorifenol		γ -Presodorifenol		α -Prechlororaphenol		Chlororaphen	
	α -PSOH (2b)		γ -PSOH (4b)		α -PCOH (5b)		(6)	
	1H	^{13}C	1H	^{13}C	1H	^{13}C	1H	^{13}C
1	3.99 <i>d</i> 6.5	59.5	3.98 <i>d</i> 6.7	59.1	3.98 <i>d</i> 6.7	59.1	-	55.9
2	5.41 <i>t</i> 6.6	124.3	5.38 <i>tq</i> 6.6, 1.8	123.9	5.40 <i>t</i> 6.8	123.9	-	163.6
3	-	139.3	-	138.5	-	139.1	-	57.1
4	1.94 <i>m</i> 1.76 <i>m</i>	35.1	1.82 <i>m</i>	33.6	1.96 <i>m</i> 1.76 <i>m</i>	34.6	1.49 <i>dq</i> 7.6, 6.9	45.0
5	1.42 <i>m</i>	36.7	1.32 <i>m</i>	35.2	1.42 <i>m</i>	35.9	0.75 <i>ddd</i> 10.0, 7.5, 5.5	47.5
6	-	50.7	-	44.4	-	50.2	-	57.6
7	-	137.1	2.23 <i>m</i>	44.6	-	136.5	-	55.6
8	-	134.4	-	160.9	-	140.0	1.43 <i>ddd</i> 13.1, 9.4, 7.5	29.1
9	2.01 <i>m</i>	48.3	1.97 <i>m</i>	43.0	2.13 <i>m</i>	45.2	1.64 <i>m</i> 1.18 <i>m</i>	39.0
10	1.51 <i>m</i>	46.5	1.22 <i>dq</i> 6.9, 10.3	46.5	1.49 <i>m</i>	45.9	0.92 <i>s</i>	12.8
11	1.50 <i>s</i>	16.5	1.48 <i>s</i>	15.9	1.49 <i>s</i>	15.9	4.91 <i>s</i> 4.57 <i>s</i>	100.4
12	0.79 <i>s</i>	19.9	0.53 <i>s</i>	14.9	0.78 <i>s</i>	19.5	0.84 <i>s</i>	11.2
13	1.49 <i>s</i>	10.3	0.93 <i>d</i> 6.8	11.4	1.50 <i>s</i>	9.5	0.891 <i>d</i> 6.8	14.6
14	1.52 <i>s</i>	12.1	4.97 <i>t</i> 2.7 4.93 <i>t</i> 2.7	103.6	2.10 <i>dq</i> 15.4, 7.6 1.94 <i>dq</i> 15.6, 7.5	19.1	1.42 <i>m</i> 1.13 <i>m</i>	26.3
15	1.02 <i>d</i> 6.8	17.7	1.12 <i>d</i> 6.9	19.1	1.03 <i>d</i> 7.6	16.9	0.896 <i>t</i> 7.2	13.8
16	0.94 <i>d</i> 7.0	13.1	0.79 <i>d</i> 6.8	11.7	0.94 <i>d</i> 7.0	12.4	0.66 <i>s</i>	9.1
17	-	-	-	-	0.92 <i>t</i> 7.5	14.0	0.76 <i>s</i>	14.1




α -PSOH (**2b**)



γ -PSOH (**4b**)



α -PCOH (**5b**)



Chlororaphen (**6**)

Figure S17: ^1H NMR spectrum of VOCs from *E. coli* expressing *Pc*-FPP-MT (*PchlO6_6045*) (in C_6D_6).




Figure S18: ^1H NMR spectrum of γ -presodorifenol (γ -PSPOH, **4b**) (in C_6D_6).




Figure S19: *dqf*-COSY spectrum of γ -presodorifenol (γ -PSPOH, **4b**) (in C_6D_6).




Figure S20: *dqf*-COSY spectrum of γ -presodorifenol (γ -PSPOH, **4b**) (in C_6D_6).




Figure S21: NOESY spectrum of γ -presodorifenol (γ -PSPOH, **4b**) (in C_6D_6).




Figure S22: NOESY spectrum of γ -presodorifenol (γ -PSPOH, **4b**) (in C_6D_6).




Figure S23: HSQC spectrum of γ -presodorifenol (γ -PSPOH, **4b**) (in C_6D_6).




Figure S24: HMBC spectrum of γ -presodorifenol (γ -PSOH, **4b**) (in C_6D_6).




Figure S25: ^1H NMR spectrum of VOCs from *E. coli* expressing *Pc*-FPP-MT (*PchlO6_6045*) and *Pc*- γ -PSPP-MT (*PchlO6_6042*) (in C_6D_6).




Figure S26: ^1H NMR spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S27: *dqf*-COSY spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S28: *dqf*-COSY spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S29: NOESY spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S30: NOESY spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S31: HSQC spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S32: HMBC spectrum of α -prechlororaphenol (α -PCOH, **5b**) (in C_6D_6).




Figure S33: ^1H NMR spectrum of VOCs from *E. coli* expressing the chlororaphen (**6**) biosynthetic gene cluster *PchlO6_6042* till *PchlO6_6045* (in C_6D_6).




Figure S34: ^1H NMR spectrum of chlororaphen (**6**) (in C_6D_6).




Figure S35: *dqf*-COSY spectrum of chlororaphen (**6**) (in C₆D₆).




Figure S36: *dqf*-COSY spectrum of chlororaphen (**6**) (in C₆D₆)




Figure S37: NOESY spectrum of chlororaphen (**6**) (in C₆D₆, d8 = 0.7 s).




Figure S38: NOESY spectrum of chlororaphen (6) (in C₆D₆).




Figure S39: HSQC spectrum of chlororaphen (**6**) (in C₆D₆).




Figure S40: HMBC spectrum of chlororaphen (6) (in C₆D₆).




Figure S41: ^{13}C $\{^1\text{H}\}$ NMR spectrum of chlororaphen (**6**) (in C_6D_6); NS 18'000.





Figure S42: ^{13}C $\{^1\text{H}\}$ NMR spectrum of chlororaphen (**6**) (in C_6D_6); NS 18'000.



References

- 1) Lemfack, M. C.; Brandt, W.; Krüger, K.; Gurowietz, A.; Djifack, J.; Jung, J. P.; Hopf, M.; Noack, H.; Junker, B.; von Reuß, S.; Piechulla, B. (2021). Reaction mechanism of the farnesyl pyrophosphate C-methyltransferase towards the biosynthesis of presodorifen pyrophosphate by *Serratia plymuthica* 4Rx13. *Scientific reports*, 11(1), 3182. <https://doi.org/10.1038/s41598-021-82521-9>
- 2a) Sievers, F.; Wilm, A.; Dineen, D. G.; Gibson, T. J.; Karplus, K.; Li, W.; Lopez, R.; McWilliam, H.; Remmert, M.; Söding, J.; Thompson, J. D.; Higgins, D. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Molecular Systems Biology* 7, 539. <https://doi.org/10.1038/msb.2011.75>
- 2b) Goujon, M.; McWilliam, H.; Li, W.; Valentin, F.; Squizzato, S.; Paern, J.; Lopez, R. (2010) A new bioinformatics analysis tools framework at EMBL-EBI. *Nucleic acids research* 38, W695-9. <https://doi.org/10.1093/nar/gkq313>
- 3) von Reuss, S.; Domik, D.; Lemfack, M. C.; Magnus, N.; Kai, M.; Weise, T.; Piechulla, B. (2018) Sodorifen Biosynthesis in the Rhizobacterium *Serratia plymuthica* Involves Methylation and Cyclization of MEP-Derived Farnesyl Pyrophosphate by a SAM-Dependent C-Methyltransferase. *Journal of the American Chemical Society* 140(37), 11855–11862. <https://doi.org/10.1021/jacs.8b08510>
- 4) Piechulla, B.; Bartelt, R.; Brosemann, A.; Effmert, U.; Bouwmeester, H.; Hippauf, F.; Brandt, W. (2016) The α -terpineol to 1,8-cineole cyclization reaction of tobacco terpene synthases. *Plant Physiology*, 172(4), 2120-2131. <https://doi.org/10.1104/pp.16.01378>
- 5) Kai, M.; Crespo, E.; Cristescu, S. M.; Harren, F. J.; Francke, W.; Piechulla, B. (2010) *Serratia odorifera*: analysis of volatile emission and biological impact of volatile compounds on *Arabidopsis thaliana*. *Applied Microbiology and Biotechnology* 88(4), 965-976. <https://doi.org/10.1007/s00253-010-2810-1>